Watch the interview with Curasight’s CEO Ulrich Krasilnikoff and Head of Research Andreas Kjaer below.
Copenhagen-based Curasight has worked tirelessly to secure a partnership deal for uTRACE. Now, the company finally announces that it has reached a deal with global radiopharmaceuticals specialist Curium, regarding the diagnosis of prostate cancer patients. The agreement include milestone payments of up to 70 MUSD, plus double-digit royalties on future sales. BioStock invited CEO Ulrich Krasilnikoff and Chief Scientific Officer Andreas Kjaer to the studio to learn more about what this means for the company.